| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccination | 127 | 2026 | 726 | 13.160 |
Why?
|
| Influenza Vaccines | 56 | 2026 | 301 | 12.020 |
Why?
|
| Influenza, Human | 42 | 2026 | 294 | 10.650 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 27 | 2026 | 92 | 6.430 |
Why?
|
| Vaccines | 36 | 2025 | 225 | 6.210 |
Why?
|
| Whooping Cough | 18 | 2025 | 65 | 6.160 |
Why?
|
| Humans | 274 | 2026 | 17622 | 5.710 |
Why?
|
| Child | 101 | 2026 | 2485 | 4.930 |
Why?
|
| Infant | 87 | 2026 | 1228 | 4.620 |
Why?
|
| Immunization | 20 | 2025 | 71 | 4.390 |
Why?
|
| Female | 183 | 2026 | 12715 | 4.180 |
Why?
|
| Pregnancy Complications, Infectious | 20 | 2026 | 157 | 4.090 |
Why?
|
| Hospitalization | 41 | 2026 | 831 | 3.970 |
Why?
|
| Male | 138 | 2026 | 10014 | 3.720 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 13 | 2022 | 64 | 3.590 |
Why?
|
| Meningococcal Vaccines | 11 | 2022 | 40 | 3.510 |
Why?
|
| Chickenpox Vaccine | 18 | 2022 | 91 | 3.460 |
Why?
|
| Adolescent | 92 | 2026 | 3625 | 3.420 |
Why?
|
| Child, Preschool | 65 | 2026 | 1455 | 3.310 |
Why?
|
| Immunization Schedule | 22 | 2026 | 127 | 3.150 |
Why?
|
| Adult | 114 | 2026 | 7621 | 3.050 |
Why?
|
| Young Adult | 77 | 2026 | 2538 | 2.900 |
Why?
|
| California | 51 | 2026 | 2433 | 2.880 |
Why?
|
| Product Surveillance, Postmarketing | 18 | 2025 | 98 | 2.870 |
Why?
|
| Vaccination Coverage | 12 | 2026 | 63 | 2.720 |
Why?
|
| United States | 84 | 2026 | 3922 | 2.690 |
Why?
|
| Measles | 6 | 2022 | 24 | 2.670 |
Why?
|
| Antibodies, Bacterial | 19 | 2023 | 34 | 2.620 |
Why?
|
| Papillomavirus Vaccines | 13 | 2024 | 114 | 2.530 |
Why?
|
| Seizures, Febrile | 8 | 2022 | 42 | 2.470 |
Why?
|
| Vaccines, Combined | 21 | 2023 | 81 | 2.340 |
Why?
|
| Retrospective Studies | 57 | 2025 | 2502 | 2.280 |
Why?
|
| Pregnancy | 47 | 2026 | 1565 | 2.220 |
Why?
|
| Pericarditis | 3 | 2022 | 11 | 2.220 |
Why?
|
| Myocarditis | 3 | 2022 | 14 | 2.210 |
Why?
|
| Infant, Newborn | 35 | 2026 | 842 | 2.140 |
Why?
|
| Vaccines, Conjugate | 18 | 2023 | 58 | 2.080 |
Why?
|
| Poliovirus Vaccine, Inactivated | 9 | 2020 | 21 | 2.070 |
Why?
|
| Emergency Service, Hospital | 19 | 2025 | 402 | 1.990 |
Why?
|
| Incidence | 34 | 2024 | 1278 | 1.960 |
Why?
|
| Pneumococcal Infections | 7 | 2023 | 43 | 1.930 |
Why?
|
| Herpes Zoster | 6 | 2023 | 82 | 1.860 |
Why?
|
| Herpes Zoster Vaccine | 6 | 2023 | 62 | 1.840 |
Why?
|
| Pneumococcal Vaccines | 10 | 2025 | 68 | 1.800 |
Why?
|
| Papillomavirus Infections | 11 | 2024 | 144 | 1.790 |
Why?
|
| Immunization, Secondary | 14 | 2022 | 58 | 1.760 |
Why?
|
| Cohort Studies | 41 | 2026 | 2502 | 1.750 |
Why?
|
| Meningococcal Infections | 7 | 2019 | 17 | 1.730 |
Why?
|
| Fever | 7 | 2022 | 52 | 1.720 |
Why?
|
| Vaccines, Inactivated | 11 | 2026 | 73 | 1.700 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 19 | 2017 | 109 | 1.680 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 8 | 2020 | 24 | 1.670 |
Why?
|
| Pregnancy Outcome | 8 | 2025 | 162 | 1.660 |
Why?
|
| Middle Aged | 59 | 2026 | 7954 | 1.590 |
Why?
|
| Immunogenicity, Vaccine | 7 | 2024 | 14 | 1.580 |
Why?
|
| Pertussis Vaccine | 6 | 2020 | 13 | 1.510 |
Why?
|
| Respiratory Syncytial Virus Infections | 4 | 2025 | 37 | 1.510 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2023 | 13 | 1.490 |
Why?
|
| Aged | 42 | 2026 | 6223 | 1.480 |
Why?
|
| Haemophilus Vaccines | 6 | 2020 | 19 | 1.480 |
Why?
|
| Case-Control Studies | 29 | 2026 | 1107 | 1.470 |
Why?
|
| Vaccines, Synthetic | 9 | 2024 | 40 | 1.460 |
Why?
|
| Mumps | 3 | 2020 | 13 | 1.450 |
Why?
|
| Neuralgia, Postherpetic | 2 | 2023 | 12 | 1.410 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 22 | 2025 | 96 | 1.400 |
Why?
|
| Disease Outbreaks | 5 | 2020 | 37 | 1.280 |
Why?
|
| Antibodies, Viral | 13 | 2024 | 73 | 1.260 |
Why?
|
| Time Factors | 23 | 2022 | 1038 | 1.250 |
Why?
|
| Rotavirus Vaccines | 10 | 2026 | 53 | 1.240 |
Why?
|
| Guillain-Barre Syndrome | 4 | 2022 | 17 | 1.230 |
Why?
|
| Adjuvants, Immunologic | 2 | 2026 | 19 | 1.090 |
Why?
|
| Immunization Programs | 7 | 2025 | 64 | 0.980 |
Why?
|
| Antiviral Agents | 3 | 2026 | 85 | 0.970 |
Why?
|
| Seasons | 13 | 2026 | 116 | 0.960 |
Why?
|
| Vaccination Refusal | 3 | 2020 | 10 | 0.950 |
Why?
|
| RNA, Messenger | 11 | 2024 | 72 | 0.930 |
Why?
|
| Neisseria meningitidis | 4 | 2019 | 10 | 0.930 |
Why?
|
| Abortion, Spontaneous | 7 | 2023 | 49 | 0.920 |
Why?
|
| Intensive Care Units, Neonatal | 3 | 2011 | 38 | 0.910 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 29 | 0.910 |
Why?
|
| Pneumonia | 2 | 2023 | 48 | 0.870 |
Why?
|
| Herpesvirus 3, Human | 5 | 2023 | 42 | 0.870 |
Why?
|
| Prenatal Care | 4 | 2020 | 129 | 0.850 |
Why?
|
| Aged, 80 and over | 19 | 2026 | 1976 | 0.840 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2023 | 1 | 0.820 |
Why?
|
| Tetanus | 5 | 2023 | 17 | 0.790 |
Why?
|
| Ambulatory Care | 6 | 2025 | 228 | 0.760 |
Why?
|
| Measles Vaccine | 3 | 2022 | 17 | 0.760 |
Why?
|
| Autoimmune Diseases | 3 | 2012 | 20 | 0.760 |
Why?
|
| Premature Birth | 8 | 2023 | 136 | 0.740 |
Why?
|
| Adaptive Immunity | 1 | 2022 | 1 | 0.730 |
Why?
|
| Risk Assessment | 16 | 2020 | 1093 | 0.730 |
Why?
|
| Sepsis | 2 | 2015 | 64 | 0.730 |
Why?
|
| Vaccines, Attenuated | 10 | 2023 | 44 | 0.720 |
Why?
|
| Cluster Analysis | 3 | 2023 | 90 | 0.720 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 7 | 2024 | 56 | 0.720 |
Why?
|
| Immunologic Factors | 1 | 2022 | 35 | 0.700 |
Why?
|
| Seizures | 4 | 2014 | 28 | 0.690 |
Why?
|
| Communicable Disease Control | 2 | 2011 | 19 | 0.690 |
Why?
|
| Health Policy | 4 | 2025 | 106 | 0.680 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2025 | 368 | 0.680 |
Why?
|
| Asthma | 4 | 2022 | 401 | 0.680 |
Why?
|
| Streptococcus pneumoniae | 7 | 2023 | 20 | 0.670 |
Why?
|
| Rubella | 1 | 2020 | 7 | 0.670 |
Why?
|
| Influenza A virus | 2 | 2020 | 13 | 0.660 |
Why?
|
| Follow-Up Studies | 11 | 2020 | 1157 | 0.650 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2020 | 7 | 0.640 |
Why?
|
| Risk Factors | 17 | 2024 | 3291 | 0.640 |
Why?
|
| Family Practice | 1 | 2020 | 41 | 0.640 |
Why?
|
| Eggs | 1 | 2020 | 8 | 0.630 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 32 | 0.630 |
Why?
|
| Blood Bactericidal Activity | 6 | 2019 | 10 | 0.620 |
Why?
|
| Autism Spectrum Disorder | 2 | 2022 | 164 | 0.620 |
Why?
|
| Health Personnel | 3 | 2025 | 135 | 0.610 |
Why?
|
| Proportional Hazards Models | 6 | 2026 | 702 | 0.610 |
Why?
|
| Logistic Models | 9 | 2020 | 866 | 0.610 |
Why?
|
| Diphtheria | 4 | 2016 | 13 | 0.590 |
Why?
|
| Chorioamnionitis | 4 | 2023 | 18 | 0.590 |
Why?
|
| Stillbirth | 5 | 2024 | 29 | 0.580 |
Why?
|
| Pediatrics | 1 | 2020 | 149 | 0.570 |
Why?
|
| Data Collection | 7 | 2021 | 234 | 0.570 |
Why?
|
| Risk | 14 | 2021 | 492 | 0.570 |
Why?
|
| Infant, Premature | 2 | 2010 | 59 | 0.560 |
Why?
|
| Antibody Formation | 1 | 2018 | 7 | 0.550 |
Why?
|
| Meningitis, Meningococcal | 1 | 2018 | 6 | 0.550 |
Why?
|
| Mothers | 3 | 2023 | 105 | 0.550 |
Why?
|
| Haemophilus Infections | 2 | 2017 | 7 | 0.540 |
Why?
|
| Respiratory Tract Infections | 3 | 2023 | 59 | 0.540 |
Why?
|
| Rotavirus Infections | 4 | 2026 | 33 | 0.540 |
Why?
|
| Severity of Illness Index | 3 | 2024 | 446 | 0.530 |
Why?
|
| Vaccine Potency | 1 | 2017 | 4 | 0.520 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 2 | 2016 | 4 | 0.520 |
Why?
|
| Status Asthmaticus | 1 | 2017 | 1 | 0.520 |
Why?
|
| Immunization, Passive | 1 | 2017 | 3 | 0.520 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 3 | 2026 | 21 | 0.520 |
Why?
|
| Tetanus Toxoid | 5 | 2018 | 11 | 0.500 |
Why?
|
| Myelitis, Transverse | 1 | 2016 | 4 | 0.500 |
Why?
|
| Research Design | 1 | 2018 | 337 | 0.490 |
Why?
|
| Schools | 6 | 2025 | 91 | 0.490 |
Why?
|
| Optic Neuritis | 1 | 2016 | 3 | 0.490 |
Why?
|
| Hearing Loss, Sudden | 1 | 2016 | 1 | 0.480 |
Why?
|
| Age Factors | 10 | 2026 | 874 | 0.480 |
Why?
|
| Serogroup | 3 | 2021 | 10 | 0.470 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2015 | 4 | 0.460 |
Why?
|
| Intubation, Intratracheal | 1 | 2015 | 6 | 0.460 |
Why?
|
| Bell Palsy | 2 | 2012 | 14 | 0.460 |
Why?
|
| Databases, Factual | 7 | 2025 | 304 | 0.450 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 38 | 0.450 |
Why?
|
| Odds Ratio | 7 | 2023 | 631 | 0.450 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 2 | 2025 | 9 | 0.450 |
Why?
|
| Chronic Disease | 2 | 2016 | 398 | 0.430 |
Why?
|
| Papillomaviridae | 2 | 2020 | 61 | 0.430 |
Why?
|
| Hepatitis B Vaccines | 5 | 2020 | 44 | 0.420 |
Why?
|
| Infant, Small for Gestational Age | 5 | 2017 | 55 | 0.420 |
Why?
|
| Population Surveillance | 4 | 2025 | 248 | 0.420 |
Why?
|
| Hepatitis A Vaccines | 4 | 2019 | 15 | 0.410 |
Why?
|
| Chickenpox | 2 | 2020 | 35 | 0.410 |
Why?
|
| Penile Diseases | 1 | 2013 | 1 | 0.400 |
Why?
|
| Urethral Diseases | 1 | 2013 | 1 | 0.400 |
Why?
|
| Vulvar Diseases | 1 | 2013 | 1 | 0.400 |
Why?
|
| Treatment Outcome | 4 | 2025 | 1161 | 0.400 |
Why?
|
| Uterine Cervical Diseases | 1 | 2013 | 2 | 0.400 |
Why?
|
| Vaginal Diseases | 1 | 2013 | 6 | 0.400 |
Why?
|
| Condylomata Acuminata | 1 | 2013 | 23 | 0.400 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2012 | 4 | 0.380 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 4 | 2017 | 31 | 0.380 |
Why?
|
| Syncope | 1 | 2012 | 11 | 0.380 |
Why?
|
| Intussusception | 4 | 2014 | 16 | 0.380 |
Why?
|
| Mandatory Programs | 2 | 2025 | 6 | 0.380 |
Why?
|
| Critical Illness | 2 | 2023 | 53 | 0.380 |
Why?
|
| Apnea | 2 | 2010 | 3 | 0.360 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2022 | 135 | 0.350 |
Why?
|
| Immunologic Memory | 2 | 2013 | 3 | 0.340 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2011 | 2 | 0.340 |
Why?
|
| Vaccines, Acellular | 5 | 2020 | 11 | 0.340 |
Why?
|
| Database Management Systems | 3 | 2020 | 14 | 0.340 |
Why?
|
| Rotavirus | 2 | 2021 | 17 | 0.340 |
Why?
|
| Insurance, Health | 3 | 2021 | 169 | 0.340 |
Why?
|
| Parents | 4 | 2022 | 301 | 0.330 |
Why?
|
| Surveys and Questionnaires | 7 | 2025 | 1296 | 0.330 |
Why?
|
| Biomedical Research | 1 | 2011 | 77 | 0.320 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 9 | 0.310 |
Why?
|
| Pamphlets | 1 | 2009 | 7 | 0.310 |
Why?
|
| Respiratory Syncytial Virus, Human | 3 | 2025 | 26 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2021 | 120 | 0.310 |
Why?
|
| Patient Discharge | 1 | 2011 | 154 | 0.300 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 16 | 0.300 |
Why?
|
| Viral Vaccines | 2 | 2023 | 12 | 0.300 |
Why?
|
| src-Family Kinases | 2 | 1999 | 2 | 0.290 |
Why?
|
| Congenital Abnormalities | 3 | 2017 | 27 | 0.290 |
Why?
|
| Prospective Studies | 10 | 2023 | 1251 | 0.290 |
Why?
|
| Cross-Sectional Studies | 9 | 2025 | 1295 | 0.280 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2017 | 14 | 0.280 |
Why?
|
| Epidemiologic Methods | 2 | 2017 | 70 | 0.270 |
Why?
|
| Electronic Health Records | 6 | 2023 | 719 | 0.260 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 380 | 0.250 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 5 | 0.240 |
Why?
|
| Cross-Over Studies | 1 | 2026 | 50 | 0.240 |
Why?
|
| HIV Infections | 2 | 2024 | 584 | 0.240 |
Why?
|
| Venous Thromboembolism | 2 | 2017 | 55 | 0.230 |
Why?
|
| Data Mining | 1 | 2025 | 17 | 0.230 |
Why?
|
| Referral and Consultation | 2 | 2025 | 161 | 0.230 |
Why?
|
| Immunoglobulin G | 4 | 2021 | 35 | 0.230 |
Why?
|
| Educational Personnel | 1 | 2025 | 1 | 0.220 |
Why?
|
| Aluminum | 2 | 2022 | 15 | 0.220 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2024 | 540 | 0.220 |
Why?
|
| Bacterial Capsules | 2 | 2017 | 7 | 0.220 |
Why?
|
| Europe | 2 | 2025 | 43 | 0.220 |
Why?
|
| Chlamydia Infections | 1 | 2024 | 23 | 0.210 |
Why?
|
| Gonorrhea | 1 | 2024 | 19 | 0.210 |
Why?
|
| Animals | 3 | 2020 | 285 | 0.200 |
Why?
|
| Mortality | 2 | 2021 | 116 | 0.200 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2022 | 4 | 0.190 |
Why?
|
| Poisson Distribution | 4 | 2016 | 85 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 51 | 0.190 |
Why?
|
| Sex Factors | 3 | 2021 | 599 | 0.190 |
Why?
|
| Respiratory Tract Diseases | 2 | 2020 | 23 | 0.190 |
Why?
|
| Pharyngitis | 1 | 2022 | 10 | 0.190 |
Why?
|
| School Health Services | 2 | 2021 | 40 | 0.190 |
Why?
|
| Eczema | 1 | 2022 | 7 | 0.190 |
Why?
|
| Intention | 1 | 2022 | 28 | 0.190 |
Why?
|
| Confidence Intervals | 3 | 2021 | 228 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 319 | 0.180 |
Why?
|
| Pregnant Women | 2 | 2020 | 46 | 0.180 |
Why?
|
| China | 1 | 2022 | 132 | 0.180 |
Why?
|
| Hepatitis A | 2 | 2019 | 11 | 0.180 |
Why?
|
| Intensive Care Units | 2 | 2024 | 105 | 0.180 |
Why?
|
| Centers for Disease Control and Prevention (U.S.) | 4 | 2014 | 32 | 0.170 |
Why?
|
| Physicians, Primary Care | 1 | 2022 | 63 | 0.170 |
Why?
|
| Trans-Activators | 2 | 1999 | 9 | 0.170 |
Why?
|
| ras Proteins | 2 | 1999 | 20 | 0.170 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 13 | 0.170 |
Why?
|
| Pandemics | 4 | 2025 | 295 | 0.170 |
Why?
|
| Regression Analysis | 3 | 2016 | 268 | 0.170 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 23 | 0.170 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 3 | 2021 | 15 | 0.170 |
Why?
|
| Nervous System Diseases | 2 | 2011 | 20 | 0.170 |
Why?
|
| Mental Disorders | 1 | 2024 | 276 | 0.170 |
Why?
|
| Circovirus | 1 | 2020 | 1 | 0.170 |
Why?
|
| Spatial Analysis | 1 | 2020 | 11 | 0.170 |
Why?
|
| Geography | 1 | 2020 | 38 | 0.170 |
Why?
|
| Linguistics | 1 | 2020 | 4 | 0.160 |
Why?
|
| Prognosis | 2 | 2020 | 609 | 0.160 |
Why?
|
| Pregnancy Trimester, First | 2 | 2017 | 43 | 0.160 |
Why?
|
| Complement System Proteins | 2 | 2018 | 4 | 0.160 |
Why?
|
| Education | 1 | 2020 | 14 | 0.160 |
Why?
|
| Bacterial Infections | 1 | 2019 | 6 | 0.160 |
Why?
|
| Professional-Family Relations | 1 | 2020 | 52 | 0.160 |
Why?
|
| Diphtheria Toxoid | 2 | 2017 | 3 | 0.160 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 22 | 0.160 |
Why?
|
| Virus Replication | 1 | 1999 | 12 | 0.150 |
Why?
|
| Influenza B virus | 3 | 2026 | 13 | 0.150 |
Why?
|
| Bacterial Vaccines | 2 | 2023 | 9 | 0.150 |
Why?
|
| Hepatitis A Virus, Human | 1 | 2019 | 5 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 56 | 0.150 |
Why?
|
| Hepatitis B virus | 1 | 1999 | 21 | 0.150 |
Why?
|
| Frail Elderly | 1 | 2019 | 8 | 0.150 |
Why?
|
| Frailty | 1 | 2019 | 12 | 0.150 |
Why?
|
| History, 21st Century | 2 | 2019 | 22 | 0.150 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2018 | 213 | 0.150 |
Why?
|
| Qualitative Research | 1 | 2020 | 290 | 0.140 |
Why?
|
| Epidemiologic Research Design | 2 | 2016 | 18 | 0.140 |
Why?
|
| Hispanic Americans | 1 | 2020 | 370 | 0.140 |
Why?
|
| Gestational Age | 3 | 2021 | 119 | 0.140 |
Why?
|
| Models, Theoretical | 1 | 2018 | 67 | 0.140 |
Why?
|
| Residence Characteristics | 1 | 2020 | 256 | 0.140 |
Why?
|
| Rabbits | 1 | 2018 | 6 | 0.140 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 527 | 0.140 |
Why?
|
| Infant Mortality | 1 | 2018 | 15 | 0.140 |
Why?
|
| Vaccines, Subunit | 1 | 2017 | 1 | 0.140 |
Why?
|
| Microcephaly | 1 | 2017 | 3 | 0.140 |
Why?
|
| Bordetella pertussis | 2 | 2020 | 4 | 0.140 |
Why?
|
| African Americans | 1 | 2020 | 429 | 0.140 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2017 | 15 | 0.130 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2017 | 9 | 0.130 |
Why?
|
| Licensure | 1 | 2017 | 4 | 0.130 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2017 | 9 | 0.130 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2017 | 10 | 0.130 |
Why?
|
| Haemophilus influenzae type b | 1 | 2017 | 4 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2019 | 269 | 0.130 |
Why?
|
| Seeds | 1 | 2017 | 1 | 0.130 |
Why?
|
| Magnoliopsida | 1 | 2017 | 1 | 0.130 |
Why?
|
| Plant Dormancy | 1 | 2017 | 1 | 0.130 |
Why?
|
| Health Maintenance Organizations | 2 | 2010 | 403 | 0.130 |
Why?
|
| Preconception Care | 1 | 2017 | 44 | 0.130 |
Why?
|
| Safety Management | 3 | 2011 | 13 | 0.130 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2017 | 34 | 0.130 |
Why?
|
| Decision Making | 1 | 2018 | 177 | 0.130 |
Why?
|
| Family Health | 1 | 2017 | 45 | 0.130 |
Why?
|
| Pregnancy Complications | 2 | 2017 | 208 | 0.120 |
Why?
|
| Maternal Age | 3 | 2023 | 74 | 0.120 |
Why?
|
| Liver Diseases | 1 | 2016 | 23 | 0.120 |
Why?
|
| Epidemiologic Studies | 1 | 2016 | 29 | 0.120 |
Why?
|
| Anaphylaxis | 1 | 2015 | 16 | 0.120 |
Why?
|
| Double-Blind Method | 3 | 2021 | 144 | 0.110 |
Why?
|
| Causality | 2 | 2012 | 35 | 0.110 |
Why?
|
| Comorbidity | 4 | 2022 | 552 | 0.110 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 5 | 0.110 |
Why?
|
| Autistic Disorder | 1 | 2017 | 115 | 0.110 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2015 | 5 | 0.110 |
Why?
|
| Sex Distribution | 2 | 2017 | 174 | 0.110 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2014 | 1 | 0.110 |
Why?
|
| Age Distribution | 2 | 2017 | 230 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2014 | 9 | 0.110 |
Why?
|
| Treatment Refusal | 1 | 2015 | 30 | 0.110 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2014 | 18 | 0.110 |
Why?
|
| Algorithms | 2 | 2017 | 227 | 0.110 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2017 | 205 | 0.110 |
Why?
|
| Medical Records | 2 | 2017 | 91 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 184 | 0.110 |
Why?
|
| DiGeorge Syndrome | 1 | 2014 | 1 | 0.110 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2014 | 40 | 0.100 |
Why?
|
| Safety | 2 | 2011 | 43 | 0.100 |
Why?
|
| Health Education | 2 | 2011 | 82 | 0.100 |
Why?
|
| Attitude to Health | 1 | 2015 | 147 | 0.100 |
Why?
|
| Opsonin Proteins | 1 | 2013 | 1 | 0.100 |
Why?
|
| Phagocytosis | 1 | 2013 | 2 | 0.100 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 2013 | 2 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 27 | 0.100 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 17 | 0.100 |
Why?
|
| Cervical Intraepithelial Neoplasia | 1 | 2013 | 16 | 0.100 |
Why?
|
| Alphapapillomavirus | 1 | 2013 | 13 | 0.100 |
Why?
|
| Graves Disease | 1 | 2012 | 3 | 0.090 |
Why?
|
| Drug Evaluation | 1 | 2012 | 6 | 0.090 |
Why?
|
| Hospital Mortality | 2 | 2023 | 135 | 0.090 |
Why?
|
| Stroke | 2 | 2019 | 309 | 0.090 |
Why?
|
| Prevalence | 4 | 2017 | 830 | 0.090 |
Why?
|
| Laboratories | 2 | 2021 | 19 | 0.090 |
Why?
|
| Advisory Committees | 2 | 2024 | 112 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 172 | 0.090 |
Why?
|
| Information Services | 1 | 2011 | 12 | 0.090 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 22 | 0.090 |
Why?
|
| Reference Values | 1 | 2011 | 86 | 0.080 |
Why?
|
| Needs Assessment | 1 | 2011 | 66 | 0.080 |
Why?
|
| Length of Stay | 1 | 2011 | 182 | 0.080 |
Why?
|
| Hematologic Diseases | 1 | 2010 | 5 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 152 | 0.080 |
Why?
|
| Hypersensitivity | 1 | 2010 | 22 | 0.080 |
Why?
|
| Antipyretics | 1 | 2010 | 4 | 0.080 |
Why?
|
| Physical Examination | 1 | 2010 | 20 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2010 | 6 | 0.080 |
Why?
|
| Monocytes | 1 | 2010 | 4 | 0.080 |
Why?
|
| Medical Audit | 1 | 2010 | 32 | 0.080 |
Why?
|
| Information Systems | 1 | 2009 | 15 | 0.080 |
Why?
|
| Public Health Surveillance | 2 | 2019 | 42 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 686 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 2009 | 37 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 1999 | 8 | 0.070 |
Why?
|
| Signal Transduction | 2 | 1999 | 33 | 0.070 |
Why?
|
| Mumps Vaccine | 1 | 2008 | 7 | 0.070 |
Why?
|
| Rubella Vaccine | 1 | 2008 | 9 | 0.070 |
Why?
|
| Poliomyelitis | 1 | 2008 | 2 | 0.070 |
Why?
|
| Bias | 2 | 2020 | 95 | 0.070 |
Why?
|
| Medicaid | 2 | 2025 | 188 | 0.070 |
Why?
|
| Serotyping | 1 | 2007 | 2 | 0.070 |
Why?
|
| Sentinel Surveillance | 1 | 2007 | 13 | 0.070 |
Why?
|
| Injections, Intramuscular | 2 | 2021 | 9 | 0.070 |
Why?
|
| Twins | 1 | 2007 | 11 | 0.060 |
Why?
|
| Diseases in Twins | 1 | 2007 | 15 | 0.060 |
Why?
|
| Siblings | 1 | 2007 | 13 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 346 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2009 | 232 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2020 | 40 | 0.060 |
Why?
|
| Mass Vaccination | 2 | 2019 | 22 | 0.060 |
Why?
|
| Propensity Score | 2 | 2017 | 80 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2006 | 8 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2006 | 66 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2020 | 99 | 0.060 |
Why?
|
| Registries | 1 | 2008 | 475 | 0.060 |
Why?
|
| International Classification of Diseases | 2 | 2017 | 85 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 384 | 0.060 |
Why?
|
| Toxoids | 1 | 2023 | 3 | 0.050 |
Why?
|
| Oxygen | 1 | 2023 | 15 | 0.050 |
Why?
|
| Macrolides | 1 | 2022 | 6 | 0.050 |
Why?
|
| Penicillins | 1 | 2022 | 5 | 0.050 |
Why?
|
| Inappropriate Prescribing | 1 | 2022 | 9 | 0.050 |
Why?
|
| RNA, Messenger, Stored | 1 | 2022 | 3 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 3 | 0.050 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 559 | 0.050 |
Why?
|
| Human papillomavirus 18 | 1 | 2022 | 3 | 0.050 |
Why?
|
| Human papillomavirus 16 | 1 | 2022 | 7 | 0.050 |
Why?
|
| Alberta | 1 | 2021 | 4 | 0.040 |
Why?
|
| Antigens | 1 | 2021 | 7 | 0.040 |
Why?
|
| Postal Service | 1 | 2022 | 72 | 0.040 |
Why?
|
| Drug Approval | 1 | 2021 | 12 | 0.040 |
Why?
|
| Forecasting | 1 | 2022 | 68 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2022 | 143 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2021 | 69 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2021 | 64 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 9 | 0.040 |
Why?
|
| Pain | 1 | 2021 | 75 | 0.040 |
Why?
|
| Policy | 1 | 2020 | 20 | 0.040 |
Why?
|
| Child Health Services | 1 | 2022 | 107 | 0.040 |
Why?
|
| Perception | 1 | 2021 | 56 | 0.040 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2020 | 1 | 0.040 |
Why?
|
| Health Facilities | 1 | 2020 | 16 | 0.040 |
Why?
|
| Attitude | 1 | 2020 | 28 | 0.040 |
Why?
|
| Managed Care Programs | 2 | 2013 | 300 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 28 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 37 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2022 | 308 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 2019 | 8 | 0.040 |
Why?
|
| Hepatitis B Virus, Woodchuck | 1 | 1999 | 1 | 0.040 |
Why?
|
| Viral Proteins | 1 | 1999 | 3 | 0.040 |
Why?
|
| DNA Primers | 1 | 1999 | 8 | 0.040 |
Why?
|
| Base Sequence | 1 | 1999 | 18 | 0.040 |
Why?
|
| Appendicitis | 1 | 2019 | 13 | 0.040 |
Why?
|
| Cell Line | 1 | 1999 | 11 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 151 | 0.040 |
Why?
|
| RNA, Viral | 1 | 1999 | 48 | 0.040 |
Why?
|
| Continental Population Groups | 1 | 2021 | 283 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 32 | 0.040 |
Why?
|
| Pancreatitis | 1 | 2019 | 54 | 0.040 |
Why?
|
| Mass Screening | 1 | 2024 | 693 | 0.040 |
Why?
|
| Viral Load | 1 | 2019 | 110 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2018 | 10 | 0.040 |
Why?
|
| Ethnic Groups | 1 | 2021 | 443 | 0.030 |
Why?
|
| Hepatitis B | 1 | 2018 | 41 | 0.030 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2017 | 1 | 0.030 |
Why?
|
| Viral Envelope Proteins | 1 | 2017 | 1 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 5 | 0.030 |
Why?
|
| Guanosine Triphosphate | 1 | 1997 | 1 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 1997 | 1 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 1997 | 1 | 0.030 |
Why?
|
| GTPase-Activating Proteins | 1 | 1997 | 1 | 0.030 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 1997 | 1 | 0.030 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 1997 | 1 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 1997 | 2 | 0.030 |
Why?
|
| Proteins | 1 | 1997 | 15 | 0.030 |
Why?
|
| Mice | 1 | 1997 | 82 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 23 | 0.030 |
Why?
|
| Infant, Low Birth Weight | 1 | 2017 | 30 | 0.030 |
Why?
|
| Equivalence Trials as Topic | 1 | 2017 | 1 | 0.030 |
Why?
|
| Biological Evolution | 1 | 2017 | 1 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2017 | 1 | 0.030 |
Why?
|
| Germination | 1 | 2017 | 1 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 46 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 179 | 0.030 |
Why?
|
| Proof of Concept Study | 1 | 2016 | 3 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 122 | 0.030 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2017 | 31 | 0.030 |
Why?
|
| Pregnancy Trimesters | 1 | 2016 | 29 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2016 | 46 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2016 | 93 | 0.030 |
Why?
|
| Topography, Medical | 1 | 2015 | 5 | 0.030 |
Why?
|
| Utilization Review | 1 | 2015 | 42 | 0.030 |
Why?
|
| Vasculitis | 1 | 2014 | 2 | 0.030 |
Why?
|
| Contraindications | 1 | 2014 | 14 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 87 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2013 | 44 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 2013 | 38 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 50 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2013 | 48 | 0.020 |
Why?
|
| Vaccines, Live, Unattenuated | 1 | 2012 | 1 | 0.020 |
Why?
|
| Narcolepsy | 1 | 2012 | 8 | 0.020 |
Why?
|
| Cranial Nerve Diseases | 1 | 2011 | 2 | 0.020 |
Why?
|
| Hepatitis A Antibodies | 1 | 2011 | 2 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 166 | 0.020 |
Why?
|
| Monitoring, Immunologic | 1 | 2011 | 4 | 0.020 |
Why?
|
| Tennessee | 1 | 2011 | 6 | 0.020 |
Why?
|
| Role | 1 | 2011 | 4 | 0.020 |
Why?
|
| Comprehension | 1 | 2011 | 19 | 0.020 |
Why?
|
| Culture | 1 | 2011 | 30 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 27 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2010 | 13 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 323 | 0.020 |
Why?
|